Apellis Pharmaceuticals Inc. (APLS), which has demonstrated robust revenue growth from its rare disease drugs, Empaveli and Syfovre, is focused on enhancing the market potential of both drugs to achieve blockbuster status.
Empaveli, known generically as Pegcetacoplan, received its initial FDA approval in May 2021 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, and potentially life-threatening blood disorder marked by persistently low hemoglobin levels, thrombosis, and debilitating symptoms.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com